Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Baker Heart Research Institute |
---|---|
Information provided by: | Baker Heart Research Institute |
ClinicalTrials.gov Identifier: | NCT00168467 |
One important clinical challenge in older individuals is maintaining mobility in the absence of pain. Peripheral arterial disease affects up to 12% of adults over 50 and impairs quality of life due to intermittent claudication causing pain and limiting mobility.
Conventional therapies have only modest effect in improving symptoms. We hypothesise that angiotensin converting enzyme inhibition (with ramipril), which causes arterial vasodilation, also improves clinical symptoms in patients with peripheral arterial disease.
Condition | Intervention | Phase |
---|---|---|
Peripheral Arterial Disease |
Drug: Ramipril |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Official Title: | The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease |
Ages Eligible for Study: | up to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Australia, Victoria | |
Alfred Hospital | |
Melbourne, Victoria, Australia, 3004 |
Principal Investigator: | Bronwyn A Kingwell, PhD | Baker Heart Research Institute |
Study ID Numbers: | 20/03 |
Study First Received: | September 9, 2005 |
Last Updated: | July 20, 2006 |
ClinicalTrials.gov Identifier: | NCT00168467 |
Health Authority: | Australia: Department of Health and Ageing Therapeutic Goods Administration |
Peripheral Vascular Diseases Vascular Diseases Ramipril |
Molecular Mechanisms of Pharmacological Action Therapeutic Uses Angiotensin-Converting Enzyme Inhibitors Enzyme Inhibitors Cardiovascular Diseases |
Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions Protease Inhibitors |